Memphasys Unveils Diagnostic Breakthrough with RoXsta™ System

Memphasys Ltd ( (AU:MEM) ) just unveiled an update.

Memphasys Limited has announced the acceptance of a manuscript in the journal Antioxidants, highlighting the diagnostic potential of their RoXsta™ antioxidant profiling system. This breakthrough underscores the system’s ability to accurately assess oxidative stress in biological fluids, offering significant applications in human health, agriculture, and beyond. The RoXsta™ system’s diagnostic capabilities position Memphasys as a leader in reproductive health and open up broader market opportunities in livestock and clinical applications, enhancing their industry positioning and offering scalable solutions for oxidative stress management.

More about Memphasys Ltd

Memphasys Limited (ASX: MEM) specializes in reproductive biotechnology for high value commercial applications. The company’s products in development include medical devices, in vitro diagnostics, and proprietary media, with a focus on reproductive health. Their Felix™ System, a key product, uses patented bio separation technology to enhance human artificial reproduction by selecting the most viable sperm cells.

YTD Price Performance: 0.0%

Average Trading Volume: 10,181,599

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: A$14.17M

For a thorough assessment of MEM stock, go to TipRanks’ Stock Analysis page.